Check for updates

#### **OPEN ACCESS**

EDITED BY Leonardo Roever, Federal University of Uberlandia, Brazil

REVIEWED BY Alexander E. Berezin, Zaporizhia State Medical University, Ukraine Francesco Bianco, Azienda Ospedaliero Universitaria Ospedali Riuniti, Italy Guizhen Zhao,

University of Michigan, United States

\*CORRESPONDENCE Min Hu Zm\_mz2144@163.com

RECEIVED 20 September 2023 ACCEPTED 08 November 2023 PUBLISHED 28 November 2023

#### CITATION

Liu Z, Yao Y, Zhang M, Ling Y, Yao X and Hu M (2023) Prevalence and adverse outcomes of pre-operative frailty in patients undergoing carotid artery revascularization: a metaanalysis.

Front. Cardiovasc. Med. 10:1297848. doi: 10.3389/fcvm.2023.1297848

#### COPYRIGHT

© 2023 Liu, Yao, Zhang, Ling, Yao and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Prevalence and adverse outcomes of pre-operative frailty in patients undergoing carotid artery revascularization: a meta-analysis

Zeyu Liu<sup>1,2</sup>, Ying Yao<sup>1,2</sup>, Meiwan Zhang<sup>1,2</sup>, Yan Ling<sup>2</sup>, Xiaoyan Yao<sup>2</sup> and Min Hu<sup>2\*</sup>

<sup>1</sup>College of Nursing, Nan Chang University, Nan Chang, China, <sup>2</sup>Department of Neurology, The Second Affiliated Hospital of Nanchang University, Nan Chang, China

**Introduction:** Frailty can lead to a decrease in the patient's resistance to interference such as injury and disease, and cause a series of complications. An increasing number of studies have found that pre-operative frailty exacerbates the occurrence of adverse events after carotid artery revascularization, but an integrated quantitative analysis is currently lacking. Therefore, we conducted a meta-analysis to evaluate the impact of pre-operative frailty on patients undergoing carotid artery revascularization.

**Method:** According to the PRISMA guidelines, we systematically searched for relevant studies on Medline, Embase, Ovid, CINAHL, Web Of Science, and Cochrane Library from establishment until June 2023. Summarize the risk of adverse outcome events through OR and 95% CI.

**Results:** A total of 16 cohort studies were included, including 1692338 patients. Among patients who underwent carotid artery revascularization surgery, the prevalence of pre-operative frailty was 36% (95% CI = 0.18–0.53, *P* < 0.001). Compared with non frail individuals, frail individuals have an increased risk of mortality (OR = 2.35, 95% CI = 1.40–3.92, *P* = 0.001, *I*<sup>2</sup> = 94%), stroke (OR = 1.33, 95% CI = 1.10–1.61, *P* = 0.003, *I*<sup>2</sup> = 71%), myocardial infarction (OR = 1.86, 95% CI = 1.51–2.30, *P* < 0.001, *I*<sup>2</sup> = 61%), and non-home discharge (OR = 2.39, 95% CI = 1.85–3.09, *P* < 0.001, *I*<sup>2</sup> = 63%).

**Conclusion:** The results of this article show that patients undergoing carotid artery revascularization have a higher prevalence of pre-operative frailty, which can lead to an increased risk of postoperative death, stroke, myocardial infarction, and non-home discharge. Strengthening the assessment and management of frailty is of great significance for patient prognosis.

**Systematic Review Registration:** https://www.crd.york.ac.uk/prospero/display\_record.php?RecordID=416234, identifier: CRD42023416234.

#### KEYWORDS

Frailty, carotid artery stenosis, surgery, adverse outcome, meta-analysis

Abbreviations

CEA, carotid endarterectomy; CAS, carotid artery stenting; T CAR, transcarotid artery revascularization; mFI-5,5-item modified frailty index; RAI, Risk Analysis Index; ACG, Johns Hopkins Adjusted Clinical Groups frailty indicators; mFI-11, 11-item modified frailty index; GFI, Groningen Frailty Indicator; CFS, Clinical Frailty Scale; CHS, Cardiovascular Health Study Index.

# 1. Introduction

Carotid artery stenosis refers to the narrowing of the carotid artery lumen by  $\geq$ 50% due to atherosclerosis, arterial dissection, arterial fibromuscular dysplasia, etc. Among them, carotid artery stenosis caused by atherosclerosis accounts for 90% of the total (1). According to whether there are relevant clinical symptoms, carotid artery stenosis can be divided into symptomatic carotid artery stenosis and asymptomatic carotid artery stenosis (2). A global analysis of the general population aged 30–79 shows that 1.5% of the total population have carotid artery stenosis with a stenosis rate of  $\geq$ 50% (2). According to statistics, carotid artery stenosis is associated with 20% to 30% of ischemic stroke and is also an important factor for stroke recurrence (3). In addition, studies have found that carotid artery stenosis also increased the risk of myocardial infarction, coronary heart disease hospitalization, and cardiovascular death (4).

Carotid artery revascularization surgery is a way of treatment for severe asymptomatic carotid artery stenosis and moderate to severe symptomatic carotid artery stenosis, mainly including carotid endarterectomy (CEA) and carotid artery stenting (CAS) (5, 6). Revascularization surgery is a beneficial supplement to standard drug therapy, with the main purpose of improving the blood supply to the brain from the ipsilateral carotid artery. It is an important means of primary or secondary prevention of ischemic stroke (7). However, studies have shown that when the prevalence and mortality rate of perioperative complications are more than3%, the benefits of revascularization surgery will be offset (8). Therefore, how to reduce postoperative complications is an important issue in perioperative treatment and nursing.

Frailty, most commonly seen in the elderly, is a syndrome that reflects reduced physiological reserves and the accumulation of comorbidities, resulting from the gradual decline of multiple physiological systems and the body's inability to maintain homeostasis (9, 10). It can lead to a decrease in the patient's resistance to interference such as injury and disease, and cause a series of complications, leading to a significant increase in acute decompensation, functional decline, and death (11–14).

Pre-operative frailty refers to a state of frailty that is determined by the health care provider before surgery using validated frailty assessment tools (15-17). Patients with preoperative frailty are different from normal frailty patients. On account of the influence of disease and the superposition of surgical stress and trauma, there is a higher incidence of preoperative frailty and postoperative adverse outcome events (15). As the adverse effects of pre-operative frailty have been confirmed by numerous studies, an increasing of researchers have begun to focus on whether pre-operative frailty can affect the occurrence of postoperative complications of carotid artery revascularization, but an integrated quantitative analysis is currently lacking. Therefore, a meta-analysis of relevant evidence is necessary, which will provide a reference direction for reducing postoperative complications of carotid arterv revascularization.

# 2. Materials and methods

#### 2.1. Protocol and registration

This study was conducted based on the Preferred Reporting Items for Systematic and Meta-analysis (PRISMA) (18) and the Meta-analysis of Observational Studies in Epidemiology checklist (MOOSE) (19). The protocol has been registered with the International Prospective Systems Review Registry (Prospero) (registration number CRD42023416234).

#### 2.2. Search strategy

We systematically searched for relevant research on Medline, Embase, Ovid, CINAHL, Web Of Science, and Cochrane Library from the establishment of the database to June 2023. The following MeSH terms or keywords were used: "frail elderly" OR "frail" OR "elderly assessment" OR "frail" OR "frail syndrome"; "carotid artery stenosis" OR "carotid endarterectomy" OR "carotid artery stenosis" OR "carotid artery revascularization". A detailed search strategy can be found in Supplementary-Material.

#### 2.3. Eligibility criteria

The inclusion criteria are as follows: (1) Patients undergoing carotid artery revascularization surgery, including CEA and CAS (including transcarotid artery revascularization, TCAR); (2) A confirmed diagnosis of frailty was made by a validated frailty assessment tool before surgery; (3) Observational studies, including prospective or retrospective cohort studies; (4) The article reports the prevalence of pre-operative frailty in patients; (5) The article reports the impact of frailty on postoperative death/stroke/myocardial infarction/non-home discharge.

Exclusion criteria: (1) Incomplete data included in the study; (2) The language of this publication is not English; (3) An article report or review published in the form of comments, conference abstracts, and cases.

## 2.4. Data extraction

Two researchers independently extracted data from eligible articles, including research characteristics (first author, publication time, country, female, number of patients, number of frail patients, study design, frailty assessment tool, database, prevalence rate)and adverse postoperative outcomes (death, stroke, myocardial infarction, non-home discharge). During the data extraction process, two researchers should reach a consensus on the extracted data, if there are differences, they would discuss with the third researcher.

# 2.5. Risk of bias assessment and certainty of evidence

Two researchers used the Newcastle Ottawa Quality Scale (NOS) (20), an evaluation tool for cohort studies, to evaluate the risk of bias for the included study. According to the contents of the scale items, six areas were evaluated, such as participant selection, confounding variables, exposure measurement, outcome evaluator blind method, incomplete result date, and selective result reporting. The total score of the scale is 9 points, according to the score, the risk of bias included in the study is divided into three levels: 0-4 points for low-quality, 5–6 points for medium quality, and  $\geq 7$  points for high-quality studies. The quality of evidence for each conclusion was assessed using GRADE Working Group guidelines, which could be divided into four categories: low, medium and high.

transformation (logistic OR), then analyze the impact of preoperative frailty on postoperative adverse outcomes using RevMan 5.4 software. Summarize the prevalence of frailty in patients using Stata 17.0 and conduct subgroup analysis based on the study design. If the degree of frailty was stratified, the data would be uniformly combined. Use the chi-square heterogeneity test to evaluate overall heterogeneity results and express them as  $I^2$  statistics. If  $I^2 \ge 50\%$  indicates heterogeneity, a random effects model would be used; Otherwise, use a fixed effects model.

# 3. Results

# 3.1. Study selection

# 2.6. Statistical analysis

Summarize the OR and 95% CI of postoperative outcome events related to pre-operative frailty and perform logarithmic

Through preliminary search, 5981 articles were obtained, and after screening based on inclusion and exclusion criteria, a total of 16 studies were included (PRISMA flow chart, Figure 1).



#### 3.2. Characteristics of the included studies

A total of 16 studies involved a total of 1,692,338 patients. Among them, 5 (21-25) were prospective cohort studies, and 11 (26-36) were retrospective cohort studies. Of the 16 studies, 1 (21) came from Portugal, 1 (28) from Canada, 2 (22, 25) from the Netherlands, and 12 (23, 24, 26, 27, 29-36) from the United States. In these studies,10 studies (21-23, 25-27, 30, 33, 35, 36) included patients undergoing CEA surgery, 3 studies (24, 29, 31) included patients undergoing CAS surgery, and 3 studies (28, 32, 34) included patients undergoing CAS or CEA surgery. A total of seven frailty assessment tools were included in the study, with four studies using 5-item modified frailty index(mFI-5), four using Risk Analysis Index (RAI), two using 11-item modified frailty index(mFI-11), two using Clinical Frailty Scale(CFS), two using Groningen Frailty Indicator (GFI), one using Johns Hopkins Adjusted Clinical Groups frailty indicators(ACG), and one using Cardiovascular Health Study Index (CHS). The other features are detailed in Supplementary Table S1.

# 3.3. Risk of bias assessment and certainty of evidence

A total of 16 studies were included, with a literature quality score ranging from 6 to 9 points. The literature quality level is at the upper middle level, with 1 literature (24) scoring 9 points, 12 (21–23, 25–33) scoring 8 points, 2 (34, 36) scoring 7 points, and 1 (35) scoring 6 points. See **Supplementary Table S2** for details. According to the results assessed by GRADE guidelines, the quality of the evidence for prevalence of pre-operative frailty in carotid artery revascularization was graded as "low", increased mortality risk was graded as "high", increased stroke risk was graded as "moderate", increased myocardial infarction risk was graded as "moderate", increased non-home discharge increased was graded as "high". See **Supplementary Table S3** for details.

#### 3.4. Prevalence of pre-operative frailty

In all studies, the prevalence of frailty ranged from 4.0% to 88.0%. Among patients undergoing carotid artery revascularization, the overall prevalence of frailty was 36.0% (95% CI = 0.18–0.53, P < 0.001). The results of the subgroup analysis showed that the prevalence of frailty was 34.0% (95% CI = 0.10–0.58, P < 0.001) in the prospective cohort study, and 36.0% (95% CI = 0.15–0.57, P < 0.001) in the retrospective cohort study. Due to significant heterogeneity between them ( $I^2 = 100\%$ , P < 0.001), a random effects model was used for analysis. See **Figure 2** for details. In addition, in pooled analyses, we found that female were more likely than male to experience pre-operative frailty. See **Figure 3** for details.

### 3.5. Mortality

Six studies (21, 27, 31, 32, 34, 36) analyzed the impact of preoperative frailty on postoperative mortality using a random effects model, and the results showed a statistically significant difference with an OR of 2.35 (95% CI = 1.40–3.92, P = 0.001,  $I^2 = 94\%$ ). Due to significant heterogeneity, subgroup analysis was conducted based on whether the data was adjusted. Five studies adjusted were included (21, 27, 31, 32, 34), with an OR of 1.79 (95% CI = 1.55–2.07, P < 0.001,  $I^2 = 4\%$ ). One study unadjusted was included (36), with an OR of 5.03 (95% CI = 4.24–5.97, P < 0.001). The results all showed statistically significant differences. See **Figure 4** for details.

#### 3.6. Stroke

Six studies (21, 27, 31, 32, 34, 35) analyzed the impact of pre-operative frailty on postoperative stroke, using a random effects model. The results showed a statistically significant difference with an OR of 1.33 (95% CI = 1.10-1.61, P = 0.003,  $I^2 = 71\%$ ). Due to significant heterogeneity, subgroup analysis was conducted based on whether the data was adjusted. Four studies adjusted were included (21, 27, 31, 32), and the results showed statistically significant differences (OR = 1.61, 95% CI = 1.39-1.87, P < 0.001,  $I^2 = 0$ ). Two studies unadjusted were included (34, 35), the results showed no statistically significant differences (OR = 1.10, 95% CI = 0.99-1.23, P = 0.09,  $I^2 = 0$ ). See Figure 5 for details.

### 3.7. Myocardial infarction

Five studies (21, 27, 31, 32, 34) analyzed the impact of preoperative frailty on postoperative myocardial infarction, using a random effects model analysis. The results showed a statistically significant difference, with an OR of 1.86 (95% CI = 1.51–2.30, P < 0.001,  $I^2 = 61\%$ ). Due to significant heterogeneity, subgroup analysis was conducted based on whether the data was adjusted. Three studies were included in the adjusted group (21, 27, 32) (OR = 1.55, 95% CI = 1.33–1.80, P < 0.001,  $I^2 = 0$ ), two studies were included in the unadjusted group (31, 34), with an OR of 2.09 (95% CI = 1.82–2.39, P < 0.001,  $I^2 = 0$ ). The results all showed statistically significant differences. See **Figure 6** for details.

#### 3.8. Non-home discharge

Three studies (26, 29, 31) analyzed the impact of pre-operative frailty on postoperative non-home discharge, using a random effects model. The results showed a statistically significant (OR = 2.39, 95% CI = 1.85–3.09, P < 0.001,  $I^2 = 63\%$ ). Due to significant heterogeneity, subgroup analysis was conducted based on whether the data was adjusted. Two studies were included in the adjusted group (29, 31), with an OR of 2.22 (95% CI = 1.67–2.95, P < 0.001,  $I^2 = 58\%$ ).One unadjusted study was included in the adjusted group (26), with an OR of 2.84 (95% CI = 2.06–3.92, P < 0.001). The results all showed statistically significant differences. See Figure 7 for details.

Study design and study	ES (95% CI)	Weight
Retrospective Cohort study		
Khan 2021	• 0.25 (0.25, 0.26)	6.29
Boyd 2021	0.17 (0.17, 0.18)	6.29
Mandelbaum 2021	0.04 (0.04, 0.04)	6.29
Rothenberg 2020(1)	0.13 (0.12, 0.13)	6.29
Pandit 2019	• 0.27 (0.27, 0.28)	6.29
Rothenberg 2020(2)	• 0.23 (0.23, 0.24)	6.29
Faateh 2021	• 0.64 (0.63, 0.65)	6.29
Arya 2016	0.37 (0.36, 0.38)	6.29
chan 2022	● 0.87 (0.87, 0.88)	6.29
Melin 2015	<ul> <li>0.88 (0.88, 0.89)</li> </ul>	6.29
Gilbertson 2020	0.10 (-0.01, 0.21)	6.14
Subgroup, DL ( $I^2 = 100.0\%$ , p = 0.000)	0.36 (0.15, 0.57)	69.03
Prospective Cohort study		
ARAÚJO–ANDRADE 2020	0.76 (0.69, 0.82)	6.24
Banning 2021	0.27 (0.20, 0.34)	6.23
Visser 2019	0.28 (0.21, 0.35)	6.23
Donald 2018	0.08 (-0.03, 0.19)	6.14
Ishihara 2019	0.32 (0.22, 0.43)	6.14
Subgroup, DL ( $I^2 = 97.9\%$ , p = 0.000)	0.34 (0.10, 0.58)	30.97
Heterogeneity between groups: $p = 0.909$		
Overall, DL ( $I^2 = 100.0\%$ , p = 0.000)	0.36 (0.18, 0.53)	100.00
	1	

Prevalence of pre-operative frailty.

	mal	e	fema	ale		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
ARAÚJO-ANDRADE	39	147	6	37	3.1%	1.87 [0.72, 4.81]	
Boyd	6489	37266	22	607	9.1%	5.61 [3.66, 8.59]	
Faateh	3210	5070	1835	2766	16.7%	0.88 [0.79, 0.97]	
Ishihara	18	61	5	10	1.7%	0.42 [0.11, 1.62] 🗲	
Khan	2775	11443	1749	6540	17.1%	0.88 [0.82, 0.94]	
Mandelbaum	34312	835837	24846	590506	17.5%	0.97 [0.96, 0.99]	-
Pandit	7021	25607	3319	12268	17.4%	1.02 [0.97, 1.07]	
Rothenberg(2)	6755	25777	3238	17092	17.4%	1.52 [1.45, 1.59]	-
Total (95% CI)		941208		629826	100.0%	1.21 [1.00, 1.45]	
Total events	60619		35020				
Heterogeneity: Tau <sup>2</sup> = 0 Test for overall effect: Z	.05; Chi² : = 1.99 (F	= 393.66, > = 0.05)	df = 7 (P	< 0.0000	1); l² = 98	% —	0.7 0.85 1 1.2 1.5 male female
GURE 3							

### 3.9. Publication bias

A publication bias test was conducted on the prevalence of preoperative frailty, and the results showed that there was a certain publication bias(Begg's test: P = 0.043 and Egger's test: P = 0.037). Due to the limited number of articles, publication bias testing was not conducted in other outcomes (37).

# 4. Discussion

This study showed that the prevalence of pre-operative frailty in carotid artery revascularization was 36.0%. Through subgroup analysis, it was found that the prevalence of frailty in prospective cohort studies was 34.0%, and in retrospective cohort studies, it was 36.0%. Patients with frailty have a higher risk of

				Odds Ratio	Odds Ratio
Study or Subgroup	log[Odds Ratio]	SE	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.1.1 adjusted					
ARAÚJO-ANDRADE 2020	0.5164	0.1624	18.3%	1.68 [1.22, 2.30]	-
Boyd 2021	1.0543	0.7272	7.8%	2.87 [0.69, 11.94]	
Khan 2021	0.8154	0.2407	16.9%	2.26 [1.41, 3.62]	
Mandelbaum 2021	0.4637	0.1027	19.1%	1.59 [1.30, 1.94]	-
Pandit 2019	0.7419	0.1387	18.7%	2.10 [1.60, 2.76]	
Subtotal (95% CI)			80.7%	1.79 [1.55, 2.07]	♦
Heterogeneity: Tau <sup>2</sup> = 0.00; C	hi² = 4.18, df = 4 (	P = 0.38)	); l² = 4%		
	D(D < 0.00001)				
Test for overall effect: $Z = 8.00$	J (P < 0.00001)				
<pre>l est for overall effect: Z = 8.00 1.1.2 unadjusted</pre>	J (P < 0.00001)				
l est for overall effect: Z = 8.00 1.1.2 unadjusted Rothenberg 2020 (1)	1.6154	0.0872	19.3%	5.03 [4.24, 5.97]	
Test for overall effect: Z = 8.00 1.1.2 unadjusted Rothenberg 2020 (1) Subtotal (95% CI)	1.6154	0.0872	19.3% <b>19.3%</b>	5.03 [4.24, 5.97] <b>5.03 [4.24, 5.97]</b>	•
Test for overall effect: Z = 8.00 1.1.2 unadjusted Rothenberg 2020 (1) Subtotal (95% CI) Heterogeneity: Not applicable	1.6154	0.0872	19.3% <b>19.3%</b>	5.03 [4.24, 5.97] <b>5.03 [4.24, 5.97]</b>	•
Test for overall effect: Z = 8.00 <b>1.1.2 unadjusted</b> Rothenberg 2020 (1) <b>Subtotal (95% CI)</b> Heterogeneity: Not applicable Test for overall effect: Z = 18.5	1.6154 53 (P < 0.00001)	0.0872	19.3% <b>19.3%</b>	5.03 [4.24, 5.97] 5.03 [4.24, 5.97]	•
Test for overall effect: Z = 8.00 <b>1.1.2 unadjusted</b> Rothenberg 2020 (1) <b>Subtotal (95% CI)</b> Heterogeneity: Not applicable Test for overall effect: Z = 18.5 <b>Total (95% CI)</b>	1.6154 53 (P < 0.00001)	0.0872	19.3% 19.3% 100.0%	5.03 [4.24, 5.97] 5.03 [4.24, 5.97] 2.35 [1.40, 3.92]	•
Test for overall effect: Z = 8.00 <b>1.1.2 unadjusted</b> Rothenberg 2020 (1) <b>Subtotal (95% CI)</b> Heterogeneity: Not applicable Test for overall effect: Z = 18.5 <b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> = 0.35; C	1.6154 53 (P < 0.00001) hi <sup>2</sup> = 89.93, df = 5	0.0872 (P < 0.00	19.3% <b>19.3%</b> <b>100.0%</b> 2001); l <sup>2</sup> =	5.03 [4.24, 5.97] 5.03 [4.24, 5.97] 2.35 [1.40, 3.92] 94%	•
<b>1.1.2 unadjusted</b> Rothenberg 2020 (1) <b>Subtotal (95% CI)</b> Heterogeneity: Not applicable Test for overall effect: Z = 18.5 <b>Total (95% CI)</b> Heterogeneity: Tau <sup>2</sup> = 0.35; C Test for overall effect: Z = 3.26	1.6154 53 (P < 0.00001) hi <sup>2</sup> = 89.93, df = 5 6 (P = 0.001)	0.0872 (P < 0.00	19.3% <b>19.3%</b> <b>100.0%</b> 0001); l <sup>2</sup> =	5.03 [4.24, 5.97] 5.03 [4.24, 5.97] 2.35 [1.40, 3.92] 94%	0.01 0.1 1 10 100

Effect of pre-operative frailty on mortality.

Study or Subgrouplog[Oc2.1.1 adjustedARAÚJO-ANDRADE 2020Boyd 2021Khan 2021Mandelbaum 2021Subtotal (95% CI)Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.0Test for overall effect: Z = 6.28 (P < 0)2.1.2 unadjustedPandit 2019Rothenberg 2020 (2)	0.2971 0.4253 0.5008 0.5068 68, df = 3 (F 0.00001)	0.2529 0.2019 0.2162 0.0943 P = 0.88) 0.0727	9.4% 12.3% 11.4% 21.5% <b>54.6%</b> ); I <sup>2</sup> = 0%	IV, Random, 95% CI 1.35 [0.82, 2.21] 1.53 [1.03, 2.27] 1.65 [1.08, 2.52] 1.66 [1.38, 2.00] 1.61 [1.39, 1.87] 1.13 [0.98, 1.30]	IV, Random, 95% Cl
2.1.1 adjusted ARAÚJO-ANDRADE 2020 Boyd 2021 Khan 2021 Mandelbaum 2021 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.0 Test for overall effect: Z = 6.28 (P < 0 2.1.2 unadjusted Pandit 2019 Rothenberg 2020 (2)	0.2971 0.4253 0.5008 0.5068 68, df = 3 (F 0.00001)	0.2529 0.2019 0.2162 0.0943 P = 0.88) 0.0727	9.4% 12.3% 11.4% 21.5% <b>54.6%</b> );   <sup>2</sup> = 0%	1.35 [0.82, 2.21] 1.53 [1.03, 2.27] 1.65 [1.08, 2.52] 1.66 [1.38, 2.00] <b>1.61 [1.39, 1.87]</b>	
ARAUJO-ANDRADE 2020 Boyd 2021 Khan 2021 Mandelbaum 2021 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.0 Test for overall effect: Z = 6.28 (P < 0 2.1.2 unadjusted Pandit 2019 Rothenberg 2020 (2)	0.2971 0.4253 0.5008 0.5068 68, df = 3 (F 0.00001)	0.2529 0.2019 0.2162 0.0943 P = 0.88) 0.0727	9.4% 12.3% 11.4% 21.5% <b>54.6%</b> );   <sup>2</sup> = 0%	1.35 [0.82, 2.21] 1.53 [1.03, 2.27] 1.65 [1.08, 2.52] 1.66 [1.38, 2.00] <b>1.61 [1.39, 1.87]</b>	
Boyd 2021 Khan 2021 Mandelbaum 2021 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.0 Test for overall effect: $Z = 6.28$ (P < 0 2.1.2 unadjusted Pandit 2019 Rothenberg 2020 (2)	0.4253 0.5008 0.5068 68, df = 3 (F 0.00001) 0.1222	0.2019 0.2162 0.0943 P = 0.88) 0.0727	12.3% 11.4% 21.5% <b>54.6%</b> );   <sup>2</sup> = 0% 23.4%	1.53 [1.03, 2.27] 1.65 [1.08, 2.52] 1.66 [1.38, 2.00] <b>1.61 [1.39, 1.87]</b> 1.13 [0.98, 1.30]	
Khan 2021 Mandelbaum 2021 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.0 Test for overall effect: $Z = 6.28$ (P < 0 2.1.2 unadjusted Pandit 2019 Rothenberg 2020 (2)	0.5008 0.5068 68, df = 3 (F 0.00001) 0.1222	0.2162 0.0943 P = 0.88) 0.0727	11.4% 21.5% <b>54.6%</b> );   <sup>2</sup> = 0% 23.4%	1.65 [1.08, 2.52] 1.66 [1.38, 2.00] <b>1.61 [1.39, 1.87]</b> 1.13 [0.98, 1.30]	
Mandelbaum 2021 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.0 Test for overall effect: $Z = 6.28$ (P < 0 2.1.2 unadjusted Pandit 2019 Rothenberg 2020 (2)	0.5068 68, df = 3 (F 0.00001) 0.1222	0.0943 P = 0.88) 0.0727	21.5% <b>54.6%</b> );   <sup>2</sup> = 0% 23.4%	1.66 [1.38, 2.00] 1.61 [1.39, 1.87] 1.13 [0.98, 1.30]	
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.0 Test for overall effect: Z = $6.28$ (P < 0 2.1.2 unadjusted Pandit 2019 Rothenberg 2020 (2)	68, df = 3 (F ).00001) 0.1222	P = 0.88) 0.0727	<b>54.6%</b> );   <sup>2</sup> = 0% 23.4%	1.61 [1.39, 1.87]	
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.0 Test for overall effect: Z = 6.28 (P < 0 <b>2.1.2 unadjusted</b> Pandit 2019 Rothenberg 2020 (2)	68, df = 3 (F 0.00001) 0.1222	P = 0.88) 0.0727	); I <sup>2</sup> = 0% 23.4%	1.13 [0.98, 1.30]	
Test for overall effect: Z = 6.28 (P < 0 2.1.2 unadjusted Pandit 2019 Rothenberg 2020 (2)	0.00001)	0.0727	23.4%	1.13 [0.98. 1.30]	
<b>2.1.2 unadjusted</b> Pandit 2019 Rothenberg 2020(2)	0.1222	0.0727	23.4%	1.13 [0.98. 1.30]	<b></b>
Pandit 2019 Rothenberg 2020(2)	0.1222	0.0727	23.4%	1.13 [0.98, 1.30]	+ <b>-</b>
Rothenberg 2020 (2)					
-	0.0583	0.0892	21.9%	1.06 [0.89, 1.26]	
Subtotal (95% CI)			45.4%	1.10 [0.99, 1.23]	
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.3	31, df = 1 (F	P = 0.58)	); I <sup>2</sup> = 0%		
Test for overall effect: Z = 1.72 (P = 0	0.09)	,			
Total (95% CI)			100.0%	1.33 [1.10, 1.61]	
Heterogeneity: Tau <sup>2</sup> = 0.03; Chi <sup>2</sup> = 17	.09, df = 5	(P = 0.00)	04); l² = 71		
Test for overall effect: $Z = 3.00$ (P = 0	).003)				
Test for subgroup differences: Chi <sup>2</sup> =	, 16.10. df =	1 (P < 1	.0001). l² :	= 93.8%	Favours nontrali Favours frail

postoperative mortality, stroke, myocardial infarction, and nonhome discharge compared to patients without frailty.

Recent researches showed that due to aging of body function, atherosclerosis, and other factors, patients undergoing carotid artery revascularization have a high degree of pre-operative frailty (38, 39). Banning (40) found that the prevalence of preoperative frailty of CEA is 23.9%, lower than the results of this study, which may be related to the inclusion of CAS patients and expanded sample size in this study.

In this meta-analysis, we found that pre-operative frailty in carotid artery revascularization increases the risk of postoperative mortality (OR = 2.35, 95% CI = 1.40–3.92, P = 0.001,  $I^2 = 94\%$ ). Karam (41) demonstrated that pre-operative frailty can predict postoperative mortality (OR = 2.06) among 67,308 hospitalized patients in vascular surgery, similar to the conclusions of this study.

The occurrence of postoperative stroke and myocardial infarction is an important indicator for evaluating the efficacy of carotid artery revascularization surgery. In this study, we found

Effect of pre-operative frailty on myocardial infarction.

				Odda Patia	Odda Patio
Study or Subaroup	log[Odds Ratio]	SE	Weight	IV Random 95% CI	IV Random 95% CI
4 1 1 adjusted		52	weight		
Faateh 2021	0 9933	0 182	26.2%	2 70 [1 89 .3 86]	
Khan 2021	0.6881	0.0774	44.9%	1.99 [1.71, 2.32]	
Subtotal (95% CI)	010001	0.0777	71.0%	2.22 [1.67, 2.95]	•
Heterogeneity: $Tau^2 = 0$	).03: Chi² = 2.38, df	f = 1 (P =	= 0.12); l <sup>2</sup> :	= 58%	
Test for overall effect: Z	2 = 5.45 (P < 0.000	01)	,.		
4.1.2 unadjusted					
Arya 2016	1.0438	0.1638	29.0%	2.84 [2.06, 3.92]	
Subtotal (95% CI)			29.0%	2.84 [2.06, 3.92]	•
Heterogeneity: Not app	licable				
Test for overall effect: Z	2 = 6.37 (P < 0.000	01)			
Total (95% CI)			100.0%	2.39 [1.85, 3.09]	•
Heterogeneity: $Tau^2 = 0$	0.03; Chi² = 5.37, d <sup>f</sup>	f = 2 (P =	= 0.07); l <sup>2</sup>	= 63%	
Test for overall effect: Z	Z = 6.68 (P < 0.000	D1)	,,		0.01 0.1 1 10 100
		, , ,			Favours nonirali Favours Irali

that the risk of postoperative stroke in frail patients was 1.33 times that of non-frail patients, and the risk of postoperative myocardial infarction was 1.83 times that of non-frail patients. Pre-operative frailty increased the risk of postoperative complications.

In addition, the important thing is that a good long-term prognosis is also a necessary condition for consideration of preventive treatment. Non-home discharge is closely related to an increased risk of complications, frequent readmissions, and death (42, 43). This study found that pre-operative frailty increased the risk of non-home discharge by 1.39-fold (OR =

2.39, 95% CI = 1.85–3.09, P < 0.001,  $I^2 = 63\%$ ), which is similar to the study results of Ebrahimian (44).

The advantage of this meta-analysis is to focus on patients with carotid artery stenosis, as frailty and carotid artery stenosis are mutually causal and exacerbating. On the one hand, insufficient blood supply to the carotid artery and the combined effects of other cardiovascular diseases drive frailty (45). On the other hand, frailty also accelerates the change of carotid central structure and atherosclerosis, further exacerbating carotid stenosis (11). Patients with carotid artery stenosis who undergoing revascularization surgery

require strong physical reserves as support during the surgery. For frail patients, the reduction of physiological reserves reduces their ability to resist intraoperative risks, leading to adverse postoperative outcomes and affecting their prognosis. Therefore, emphasizing perioperative frailty management is of great significance for the rehabilitation of patients with carotid artery stenosis.

The information obtained from pre-operative frailty assessment can be used to alert patients to surgical risks and develop personalized treatment plans, and frailty patients often tend to prefer less invasive or conservative treatment pathways (46). At the same time, clinical doctors and frail patients can jointly discuss the benefits of surgery, and make collaborative decisions centered on the patient, achieving the goal of balancing potential risks and improving quality of life.

Frailty can also be seen as a potential therapeutic goal, aimed at optimizing the patient's physical strength, nutrition, and functional status before and after surgery by managing frailty. The sustained stress experienced by frail patients during major surgeries can deplete their physiological reserves, leading to progressive decompensation after surgery. Early pre-habilitation can avoid the risk of partial loss in advance (47). For example, pre-operative physical exercise and enhanced nutrition or medication can be used to enhance body function to cope with the risks and trauma caused by surgery (48). Hall (49) found that through comprehensive frailty screening and early management of patients undergoing elective surgery, the mortality of frailty patients decreased from 12.2% to 3.8%, and treatment including ventilator management and postoperative dialysis was also better maintained.

Furthermore, frailty assessment can provide a reference for the allocation of nursing resources and the adjustment of nursing strategies for frail patients undergoing carotid arterv revascularization. Frailty patients often combine physical, psychological, social, and other aspects of frailty into one (50). In postoperative care, in addition to connecting with pre-operative pre-rehabilitation, attention should also be paid to the comprehensive physical and mental recovery of patients. Research has shown that frail patients often do not want to face up to the "losses" caused by their frailty, believing that frailty will reduce their sense of self-identity, quality of life, or life goals, so often presenting different value needs (51). Therefore, frailty management requires the joint efforts of doctors, patients, and family members to explore the core values of patients. Only by understanding the optimal needs of frail patients can personalized nursing strategies and health education plans be better formulated.

There are many tools to assess frailty in clinical practice, medical staff should choose assessment tools that are in line with patients' conditions. For example, mFI scale has a wide range of assessment fields and high sensitivity, but it requires a large amount of clinical information, which is extremely tedious and time-consuming (52). However, the CFS scale shows a good psychometric property, a short assessment time, and does not require additional equipments. At present, there is evidence that the CFS scale tool is suitable for the assessment of cardiovascular disease patients, which can be further verified in the future (53). In addition, many studies define

the evaluation results as binary cut-off, but the development of frailty is a dynamic process, and data analysis should reflect this continuity (54). So, presenting the results in the way of categorical and/or continuous fashion will have greater clinical significance.

The American Society of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) and the American Geriatric Society (AGS) (55) recommend that all elderly surgical patients should have a frailty score record on admission. The National Confidential Enquiry into Patient Outcome and Death publication in the UK also pointed out that frailty needs to be considered as an important surrogate markers of risk in the perioperative period (56). However, in the fifth NELA report (57), it was pointed out that among frail patients aged 65 and above, only 36.9% of doctors provide medication to the elderly during the postoperative period, indicating that there is currently insufficient emphasis on frailty management in clinical practice and the need to further strengthen medical staff's awareness.

#### 4.1. Limitations

There are also several shortcomings in this study. First of all, there is no strict limit on inclusion in the research database, and some data may overlap. Secondly, due to the diversity of assessment tools for frailty and the varying definitions of multiple frailties, it is not possible to uniformly define assessment tools. Finally, the prevalence of pre-operative frailty have heterogeneity and publication bias, so the interpretation of the results should be more cautious.

### 4.2. Future directions

This study has revealed the role of pre-operative frailty in adverse outcomes after carotid revascularization, and it can be further clarified whether it has different effects on surgical types in the future. It is also meaningful to explore the factors that influence pre-operative frailty in carotid artery revascularization, which can help us find more targeted ways to improve preoperative frailty. In addition, some researchers have found that pre-operative frailty plays a different role in patients with symptomatic and asymptomatic carotid stenosis, but the evidence is limited now, so more studies are needed in the future.

# 5. Conclusion

In this study, we have found that the prevalence of preoperative frailty in carotid artery revascularization was 36% and pre-operative frailty could increase the risk of mortality, stroke, myocardial infarction, and non-home discharge after carotid artery revascularization. In clinical practice, we should strengthen management strategies for pre-operative frailty to reduce the risk of adverse events after carotid artery revascularization.

#### Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

#### Author contributions

ZL: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Resources, Writing – original draft. YY: Data curation, Formal Analysis, Investigation, Project administration, Resources, Writing – review & editing. MZ: Data curation, Formal Analysis, Investigation, Resources, Writing – review & editing. YL: Conceptualization, Supervision, Writing – review & editing. XY: Writing – review & editing. MH: Conceptualization, Supervision, Writing – review & editing.

# Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

# References

1. Inzitari D, Eliasziw M, Gates P, Sharpe BL, Chan RK, Meldrum HE, et al. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American symptomatic carotid endarterectomy trial collaborators. *N Engl J Med.* (2000) 342(23):1693–700. doi: 10.1056/nejm200006083422302

2. Song P, Fang Z, Wang H, Cai Y, Rahimi K, Zhu Y, et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. *Lancet Glob Health*. (2020) 8(5):e721–9. doi: 10.1016/s2214-109x(20)30117-0

3. Chu B, Ferguson MS, Chen H, Hippe DS, Kerwin WS, Canton G, et al. Magnetic resonance imaging features of the disruption-prone and the disrupted carotid plaque. *JACC Cardiovasc Imaging*. (2009) 2(7):883–96. doi: 10.1016/j.jcmg.2009.03.013

4. Sirimarco G, Amarenco P, Labreuche J, Touboul PJ, Alberts M, Goto S, et al. Carotid atherosclerosis and risk of subsequent coronary event in outpatients with atherothrombosis. *Stroke.* (2013) 44(2):373–9. doi: 10.1161/strokeaha.112.673129

5. Eckstein HH, Kühnl A, Berkefeld J, Lawall H, Storck M, Sander D. Diagnosis, treatment and follow-up in extracranial carotid stenosis. *Dtsch Arztebl Int.* (2020) 117(47):801-7. doi: 10.3238/arztebl.2020.0801

6. Howard DPJ, Gaziano L, Rothwell PM. Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis. *Lancet Neurol.* (2021) 20(3):193–202. doi: 10.1016/s1474-4422 (20)30484-1

7. Naylor R, Rantner B, Ancetti S, de Borst GJ, De Carlo M, Halliday A, et al. Editor's choice—European society for vascular surgery (Esvs) 2023 clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease. *Eur J Vasc Endovasc Surg.* (2023) 65(1):7–111. doi: 10.1016/j.ejvs. 2022.04.011

8. Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 Esc guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (Esvs): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesendorsed by: the European stroke organization (Eso)the task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (Esc) and of the European society for vascular surgery (Esvs). *Eur Heart J.* (2018) 39(9):763–816. doi: 10.1093/ eurheart/jchx095

9. Hakeem FF, Maharani A, Todd C, O'Neill TW. Development, validation and performance of laboratory frailty indices: a scoping review. *Arch Gerontol Geriatr.* (2023) 111:104995. doi: 10.1016/j.archger.2023.104995

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

#### Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2023. 1297848/full#supplementary-material

10. Goede V, Neuendorff NR, Schulz RJ, Hormigo AI, Martinez-Peromingo FJ, Cordoba R. Frailty assessment in the care of older people with haematological malignancies. *Lancet Healthy Longev.* (2021) 2(11):e736–45. doi: 10.1016/s2666-7568(21)00184-7

11. Drudi LM, Ades M, Landry T, Gill HL, Grenon SM, Steinmetz OK, et al. Scoping review of frailty in vascular surgery. *J Vasc Surg.* (2019) 69(6):1989–1998.e2. doi: 10. 1016/j.jvs.2018.10.053

12. Xue H, Huang C, Zhu Q, Zhou S, Ji Y, Ding X, et al. Relationships among cognitive function, frailty, and health outcome in community-dwelling older adults. *Front Aging Neurosci.* (2021) 13:790251. doi: 10.3389/fnagi.2021.790251

13. Czobor NR, Lehot JJ, Holndonner-Kirst E, Tully PJ, Gal J, Szekely A. Frailty in patients undergoing vascular surgery:a narrative review of current evidence. *Ther Clin Risk Manag.* (2019) 15:1217–32. doi: 10.2147/tcrm.S217717

14. Kennedy CA, Shipway D, Barry K. Frailty and emergency abdominal surgery: a systematic review and meta-analysis. *Surgeon*. (2022) 20(6):e307–14. doi: 10.1016/j. surge.2021.11.009

15. van der Vlies E, Los M, Stijns PEF, van Hengel M, Blaauw NMS, Bos WJW, et al. Preoperative frailty and outcome in patients undergoing radical cystectomy. *BJU Int.* (2020) 126(3):388–95. doi: 10.1111/bju.15132

16. Aceto P, Bassi P, Sollazzi L, Racioppi M, Fortunato G, Di Gianfrancesco L, et al. Implementation of frailty preoperative assessment to predict outcome in patients undergoing urological surgery: a systematic review and meta-analysis. *BJU Int.* (2021) 127(5):507–17. doi: 10.1111/bju.15314

17. Revenig LM, Canter DJ, Taylor MD, Tai C, Sweeney JF, Sarmiento JM, et al. Too frail for surgery? Initial results of a large multidisciplinary prospective study examining preoperative variables predictive of poor surgical outcomes. J Am Coll Surg. (2013) 217(4):665–670.e1. doi: 10.1016/j.jamcollsurg.2013.06.012

18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The prisma 2020 statement: an updated guideline for reporting systematic reviews. *Br Med J.* (2021) 372:n71. doi: 10.1136/bmj.n71

19. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (moose) group. *JAMA*. (2000) 283(15):2008–12. doi: 10.1001/jama.283.15.2008

20. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* (2010) 25 (9):603–5. doi: 10.1007/s10654-010-9491-z

21. Araújo-Andrade L, Rocha-Neves JP, Duarte-Gamas L, Pereira-Neves A, Ribeiro H, Pereira-Macedo J, et al. Prognostic effect of the new 5-factor modified frailty index

in patients undergoing carotid endarterectomy with regional anesthesia—a prospective cohort study. Int J Surg. (2020) 80:27–34. doi: 10.1016/j.ijsu.2020.05.074

22. Banning LBD, El Moumni M, Visser L, van Leeuwen BL, Zeebregts CJ, Pol RA. Frailty leads to poor long-term survival in patients undergoing elective vascular surgery. J Vasc Surg. (2021) 73(6):2132–2139.e2. doi: 10.1016/j.jvs.2020.10.088

23. Donald GW, Ghaffarian AA, Isaac F, Kraiss LW, Griffin CL, Smith BK, et al. Preoperative frailty assessment predicts loss of independence after vascular surgery. *J Vasc Surg.* (2018) 68(5):1382–9. doi: 10.1016/j.jvs.2018.02.044

24. Ishihara H, Oka F, Goto H, Nishimoto T, Okazaki K, Sadahiro H, et al. Impact of frailty on medium-term outcome in asymptomatic patients after carotid artery stenting. *World Neurosurg.* (2019) 127:e396–9. doi: 10.1016/j.wneu.2019.03.135

25. Visser L, Banning LBD, El Moumni M, Zeebregts CJ, Pol RA. The effect of frailty on outcome after vascular surgery. *Eur J Vasc Endovasc Surg.* (2019) 58(5):762–9. doi: 10.1016/j.ejvs.2019.04.031

26. Arya S, Long CA, Brahmbhatt R, Shafii S, Brewster LP, Veeraswamy R, et al. Preoperative frailty increases risk of *non-home* discharge after elective vascular surgery in home-dwelling patients. *Ann Vasc Surg.* (2016) 35:19–29. doi: 10.1016/j. avsg.2016.01.052

27. Boyd S, Tse W, Lavingia K, Amendola M. Frailty measurement and implications for cerebrovascular disease management in a veteran based population. *Ann Vasc Surg.* (2021) 76:134–41. doi: 10.1016/j.avsg.2021.04.026

28. Chan V, Rheaume AR, Chow MM. Impact of frailty on 30-day death, stroke, or myocardial infarction in severe carotid stenosis: endarterectomy versus stenting. *Clin Neurol Neurosurg.* (2022) 222:107469. doi: 10.1016/j.clineuro.2022.107469

29. Faateh M, Kuo PL, Dakour-Aridi H, Aurshina A, Locham S, Malas M. Frailty as a predictor of outcomes for patients undergoing carotid artery stenting. *J Vasc Surg.* (2021) 74(4):1290–300. doi: 10.1016/j.jvs.2021.03.038

30. Gilbertson EA, Bailey TR, Kraiss LW, Griffin CL, Smith BK, Sarfati M, et al. Long-term impact of vascular surgery stress on frail older patients. *Ann Vasc Surg.* (2021) 70:9–19. doi: 10.1016/j.avsg.2020.06.048

31. Khan MA, Elsayed N, Naazie I, Ramakrishnan G, Kashyap VS, Malas MB. Impact of frailty on postoperative outcomes in patients undergoing transcarotid artery revascularization (Tcar). *Ann Vasc Surg.* (2022) 84:126–34. doi: 10.1016/j. avsg.2021.12.085

32. Mandelbaum AD, Hadaya J, Ulloa JG, Patel R, McCallum JC, De Virgilio C, et al. Impact of frailty on clinical outcomes after carotid artery revascularization. *Ann Vasc Surg.* (2021) 74:111–21. doi: 10.1016/j.avsg.2020.12.039

33. Melin AA, Schmid KK, Lynch TG, Pipinos II, Kappes S, Longo GM, et al. Preoperative frailty risk analysis index to stratify patients undergoing carotid endarterectomy. *J Vasc Surg.* (2015) 61(3):683–9. doi: 10.1016/j.jvs. 2014.10.009

34. Pandit V, Lee A, Zeeshan M, Goshima K, Tan TW, Jhajj S, et al. Effect of frailty syndrome on the outcomes of patients with carotid stenosis. *J Vasc Surg.* (2020) 71 (5):1595–600. doi: 10.1016/j.jvs.2019.08.235

35. Rothenberg KA, George EL, Barreto N, Chen R, Samson K, Johanning JM, et al. Frailty as measured by the risk analysis index is associated with long-term death after carotid endarterectomy. *J Vasc Surg.* (2020) 72(5):1735–1742.e3. doi: 10.1016/j.jvs. 2020.01.043

36. Rothenberg KA, George EL, Trickey AW, Barreto NB, Johnson TM 2nd, Hall DE, et al. Assessment of the risk analysis index for prediction of mortality, major complications, and length of stay in patients who underwent vascular surgery. *Ann Vasc Surg.* (2020) 66:442–53. doi: 10.1016/j.avsg.2020.01.015

37. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in metaanalyses of randomised controlled trials. *Br Med J.* (2011) 343(5):d4002. doi: 10. 1136/bmj.d4002

38. DeAngelo MM, Holeman TA, Peacock JB, Smith BK, Kraiss LW, Hales JB, et al. Impact of frailty on risk of long-term functional decline following vascular surgery. *J Vasc Surg.* (2023) 77(2):515–22. doi: 10.1016/j.jvs.2022.08.011

39. Partridge JS, Fuller M, Harari D, Taylor PR, Martin FC, Dhesi JK. Frailty and poor functional status are common in arterial vascular surgical patients and

affect postoperative outcomes. Int J Surg. (2015) 18:57-63. doi: 10.1016/j.ijsu. 2015.04.037

40. Banning LBD, Benjamens S, Bokkers RPH, Zeebregts CJ, Pol RA. Role of Pre-operative frailty status in relation to outcome after carotid endarterectomy: a systematic review. *Ann Transl Med.* (2021) 9(14):1205. doi: 10.21037/atm-20-7225

41. Karam J, Tsiouris A, Shepard A, Velanovich V, Rubinfeld I. Simplified frailty index to predict adverse outcomes and mortality in vascular surgery patients. *Ann Vasc Surg.* (2013) 27(7):904–8. doi: 10.1016/j.avsg.2012.09.015

42. Edgerton JR, Herbert MA, Mahoney C, Armstrong D, Dewey TM, Holper E, et al. Long-term fate of patients discharged to extended care facilities after cardiovascular surgery. *Ann Thorac Surg.* (2013) 96(3):871–7. doi: 10.1016/j. athoracsur.2013.04.041

43. Ottenbacher KJ, Karmarkar A, Graham JE, Kuo YF, Deutsch A, Reistetter TA, et al. Thirty-day hospital readmission following discharge from postacute rehabilitation in fee-for-service medicare patients. *JAMA*. (2014) 311(6):604–14. doi: 10.1001/jama.2014.8

44. Ebrahimian S, Lee C, Tran Z, Sakowitz S, Bakhtiyar SS, Verma A, et al. Association of frailty with outcomes of resection for colonic volvulus: a national analysis. *PLoS One.* (2022) 17(11):e0276917. doi: 10.1371/journal.pone.0276917

45. Wang C, Fang X, Tang Z, Hua Y, Zhang Z, Gu X, et al. Frailty in relation to the risk of carotid atherosclerosis and cardiovascular events in Chinese communitydwelling older adults: a five-year prospective cohort study. *Exp Gerontol.* (2023) 180:112266. doi: 10.1016/j.exger.2023.112266

46. Rane M, Orkaby AR. Considerations for carotid artery disease management in a frail population. *Exp Gerontol.* (2021) 152:111426. doi: 10.1016/j.exger.2021.111426

47. Coca-Martinez M, Carli F. Prehabilitation: who can benefit? Eur J Surg Oncol. (2023) 6:106979. doi: 10.1016/j.ejso.2023.07.005

48. Yueh FR, Pan JH, Lee HF, Yen M, Hu FW. A qualitative exploration of older patients' experiences with frailty and related management strategies. *J Nurs Res.* (2023) 31(4):e283. doi: 10.1097/jnr.00000000000565

49. Hall DE, Arya S, Schmid KK, Carlson MA, Lavedan P, Bailey TL, et al. Association of a frailty screening initiative with postoperative survival at 30,180,and 365 days. *JAMA Surg.* (2017) 152(3):233–40. doi: 10.1001/jamasurg.2016.4219

50. Gobbens RJ, van Assen MA, Luijkx KG, Wijnen-Sponselee MT, Schols JM. Determinants of frailty. *J Am Med Dir Assoc.* (2010) 11(5):356–64. doi: 10.1016/j. jamda.2009.11.008

51. La Grouw Y, Bannink D, van Hout H. Care professionals manage the future, frail older persons the past explaining why frailty management in primary care doesn't always work. *Front Med.* (2020) 7:489. doi: 10.3389/fmed.2020.00489

52. Conlon M, Thommen R, Kazim SF, Dicpinigaitis AJ, Schmidt MH, McKee RG, et al. Risk analysis index and its recalibrated version predict postoperative outcomes better than 5-factor modified frailty Index in traumatic spinal injury. *Neurospine*. (2022) 19(4):1039–48. doi: 10.14245/ns.2244326.163

53. Welsh SA, Pearson RC, Hussey K, Brittenden J, Orr DJ, Quinn T. A systematic review of frailty assessment tools used in vascular surgery research. *J Vasc Surg.* (2023) S0741-5214(23):01317-4. doi: 10.1016/j.jvs.2023.06.010

54. Rockwood K, Theou O. Using the clinical frailty scale in allocating scarce health care resources. *Can Geriatr J.* (2020) 23(3):210–5. doi: 10.5770/cgj.23.463

55. Chow WB, Rosenthal RA, Merkow RP, Ko CY, Esnaola NF. Optimal preoperative assessment of the geriatric surgical patient: a best practices guideline from the American college of surgeons national surgical quality improvement program and the American geriatrics society. *J Am Coll Surg.* (2012) 215(4):453–66. doi: 10.1016/j.jamcollsurg.2012.06.017

56. Wilkinson K, Martin I, Gough M, Stewart J, Lucas S, Freeth H, et al. An age old problem: a review of the care received by elderly patients undergoing surgery. London (2010). Available at: http://www.ncepod.org.uk/2010report3/downloads/EESE\_fullReport.pdf

57. National Emergency Laparotomy Audit. *The second patient report of the national emergency laparotomy audit (NELA)*. London (2016). Available at: http://www.nela. org.uk/reports